MIRATI THERAPEUTICS INC (MRTX)
US60468T1051 - Common Stock
Bristol Myers stock cut at Redburn Atlantic (NYSE:BMY)
Redburn Atlantic downgrades Bristol-Myers Squibb (BMY) due to headwinds against its products despite the company's recent buyout deals. Read more here.
Billionaire Joe Lewis Nets 730% Gain on Stock Behind US Charges
British billionaire Joe Lewis has sold his stake in a biotechnology firm at the center of the US insider-trading case in which he pleaded guilty this week, cementing an eight-fold gain.
Bristol Myers Squibb completes Mirati acquisition (NYSE:BMY)
Bristol Myers Squibb (BMY) closes its acquisition of Mirati Therapeutics (MRTX) and sees $0.35 per share adj. earnings impact from the deal. Read more here.
Bristol Myers Squibb closes Mirati acquisition (NYSE:BMY)
Bristol Myers Squibb (BMY) closes its acquisition of Mirati Therapeutics (MRTX) and sees $0.35 per share adj. earnings impact from the deal. Read more here.
Mirati's Krazati gets EU conditional approval for lung cancer (NASDAQ:MRTX)
Mirati (MRTX) receives EU conditional approval for its drug Krazati in the treatment of lung cancer with KRAS G12C mutations. Read more here.
Bristol-Myers looking for smaller deals after 2023 shopping spree: report (NYSE:BMY)
Bristol Myers Squibb (BMY) reportedly expects to launch 16 new products by the end of the decade, but will be looking for smaller deals after its 2023 shopping
Bristol-Myers Squibb stock cut to Neutral at BofA (NYSE:BMY)
Bank of America downgrades Bristol-Myers Squibb (BMY) to Neutral due to concerns over upcoming patent expiries. Read more here.
Amgen says FDA snubbed full approval for Lumakras
Amgen's (AMGN) lung cancer therapy Lumakras faces a setback as the FDA declines full approval, citing the need for data from another trial. Read more heree.
Mirati Therapeutics stock gains as HSR waiting period for sale to Bristol-Myers expires
Mirati Therapeutics (MRTX) rises 1.2% in premarket trading as waiting period for its sale to Bristol-Myers expires, according to an 8-K filing.
Billionaire Joe Lewis Keeps Trading Stocks Behind US Insider-Trading Charges
Joe Lewis, the British billionaire behind one of the world’s biggest investing fortunes, continues to buy and sell stocks at the center of US insider-trading allegations against him.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MRTX, HES, SIX, MIRO
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
/PRNewswire/ -- USA News Group - According to the European Cancer Information System (ECIS), new cancer cases and deaths are on the rise in the EU. Sadly, this...
3 Resilient Stocks with Massive Potential to Boost Your Wealth
These three stocks with massive potential can make patient investors fabuslously wealthy as they come roaring back to life.
3 Biotech Stocks That Could Boom or Bust by 2025
Biotech stocks are popular with investors because they sometimes provide tremendous rewards. Here are three to buy for a potential payday.
3 Biotech Stocks That Could Boom or Bust by 2025
InvestorPlace - Stock Market News, Stock Advice & Trading Tips InvestorPlace published an article last December about the seven hottest biotec...
Moore Kuehn Encourages PCTI, MRTX, CSTR, and BBAI Investors to Contact Law Firm
/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...
Mirati lung cancer therapy endorsed in EU (NASDAQ:MRTX)
Mirati Therapeutics' (MRTX) KRAS inhibitor, KRAZATI, receives positive opinion from an expert panel in EU as a targeted therapy for lung cancer. Read more here.
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
/PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced that following a re-examination procedure,...
3 No-Brainer Stocks to Buy With $500 Right Now
A reasonably modest amount of money can go a long way when it's invested in time-tested businesses with sustained catalysts.
Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
/PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced the United Kingdom's Medicines and...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SP, PCTI, MRTX
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Moore Kuehn Encourages PNT, VERY, MRTX, and ORTX Investors to Contact Law Firm
/PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential...
Bristol-Myers was only firm that made real offer for Mirati Therapeutics
Bristol-Myers Squibb emerges as the sole bidder for cancer drug maker Mirati Therapeutics, offering $58 in cash and a $12 share contingent value right.
Bristol-Myers was only firm that made real bid for Mirati Therapeutics
Bristol-Myers Squibb emerges as the sole bidder for cancer drug maker Mirati Therapeutics, offering $58 in cash and a $12 share contingent value right.
7 Healthcare Stocks That Can Cure a Lackluster Portfolio
Take a position in these companies' stocks to achieve long-term gains and give a jolt to your investment portfolio.
Mirati Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer (NSCLC)
/PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced updated results from the KRYSTAL-7 Phase 2...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CNSL, PCTI, SP, MRTX
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
Amgen Stock Surges To 10-Month High, Up 4% On An Unexpected Upgrade
The company has growing pipeline optionality, according to the upgrade report.